APC: CC: July 14, 2023

End Drug Shortages Act intro’d in Congress

The legislation would expand the sources the FDA may use to declare drug shortages. read more →
FDA tirzepatide ‘reconsideration’ period extended

FDA agreed to extend until December 19 a final report on tirzepatide availability to the court. read more →
NPR hits the GLP-1 nail on the head

A National Public Radio piece this week tackled the issue of compounded GLP-1 drugs and got the facts and nuance just right. read more →
CALL TO ACTION: Tell FDA to deny drugmakers’ request

Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →
APC to FDA: Just say no to Lilly

This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →
California BOP sends proposed compounding regs to comment period

The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →
Checking in on the post-Chevron fallout

What’s happened in the world of federal regulation since the end of Chevron? read more →
Hi, Noom!

Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

Big Buttons